Efficacy of 12-month treatment of neovascular age-related macular degeneration with intravitreal bevacizumab based on individually determined injection strategies after three consecutive monthly injections

Acta Ophthalmologica

Volumn 89, Issue 7, 2011, Pages 647-653

  Mekjavic, Polona Jaki ^a   Kraut, Aleksandra ^a   Urbancic, Mojca ^a   Lenassi, Eva ^a   Hawlina, Marko ^a  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

age related macular degeneration; anti VEGF; Avastin ; bevacizumab; choroidal neovascularization; intravitreal injections; loading dose treatment strategy; vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB;

ADULT; AGED; ARTICLE; CATARACT; CLINICAL EVALUATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; EYE TOXICITY; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; HUMAN; INTRAOCULAR PRESSURE ABNORMALITY; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; RETINA FLUORESCEIN ANGIOGRAPHY; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA HOLE; RETINA TEAR; TREATMENT DURATION; UVEITIS; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; RETREATMENT; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 80155165322     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/j.1755-3768.2009.01740.x     Document Type: Article

References (32)

1. Aiello LP, Brucker AJ, Chang S, et al., (2004): Evolving guidelines for intravitreous injections. Retina 24: S3-S19. (Pubitemid 39391785)
2. Aisenbrey S, Ziemssen F, Volker M, Gelisken F, Szurman P, Jaissle G, Grisanti S, &, Bartz-Schmidt KU, (2007): Intravitreal bevacizumab (Avastin) for occult choroidal neovascularization in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 245: 941-948. (Pubitemid 46979534)
3. Algvere PV, Steen B, Seregard S, &, Kvanta A, (2008): A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations. Acta Ophthalmol 86: 482-489.
4. Arevalo JF, Fromow-Guerra J, Sanchez JG, Maia M, Berrocal MH, Wu L, Saravia MJ, &, Costa RA, (2008): Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up. Retina 28: 1387-1394.
5. Arias L, Caminal JM, Casas L, Masuet C, Badia MB, Rubio M, Pujol O, &, Arruga J, (2008): A study comparing two protocols of treatment with intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Br J Ophthalmol 92: 1636-1641.
6. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, &, Giust MJ, (2006): Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113: 363-372.
7. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat NK, &, Singh RJ, (2007): Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 114: 2179-2182. (Pubitemid 350181137)
8. Bashshur ZF, Bazarbachi A, Schakal A, Haddad ZA, El Haibi CP, &, Noureddin BN, (2006): Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 142: 1-9. (Pubitemid 43946791)
9. Bashshur ZF, Haddad ZA, Schakal A, Jaafar RF, Saab M, &, Noureddin BN, (2008): Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study. Am J Ophthalmol 145: 249-256.
10. Bressler NM, Bressler SB, Congdon NG, et al., (2003): Potential public health impact of Age-Related Eye Disease Study results: AREDS report no. 11. Arch Ophthalmol 121: 1621-1624. (Pubitemid 37392370)
11. Cleary CA, Jungkim S, Ravikumar K, Kelliher C, Acheson RW, &, Hickey-Dwyer M, (2008): Intravitreal bevacizumab in the treatment of neovascular age-related macular degeneration, 6- and 9-month results. Eye 22: 82-86.
12. Ferrara N, (2004): Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25: 581-611. (Pubitemid 39099316)
13. Ferrara N, Hillan KJ, Gerber HP, &, Novotny W, (2004): Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3: 391-400. (Pubitemid 38618122)
14. Ferris FL III, Fine SL, &, Hyman L, (1984): Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 102: 1640-1642. (Pubitemid 15204559)
15. Fong KCS, Kirkpatrick N, Mohamed Q, &, Johnson RLJ, (2008): Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration using a variable frequency regimen in eyes with no previous treatment. Clin Experiment Ophthalmol 36: 748-755.
16. Fung AE, Rosenfeld PJ, &, Reichel E, (2006): The international intravitreal bevacizumab safety survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 90: 1344-1349. (Pubitemid 44702055)
17. Fung AE, Lalwani GA, Rosenfeld PJ, et al., (2007): An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 143: 566-583.
18. Giansanti F, Virgili G, Bini A, Rapizzi E, Giacomelli G, Donati MC, Verdina T, &, Menchini U, (2007): Intravitreal bevacizumab therapy for choroidal neovascularization secondary to age-related macular degeneration: 6-month results of an open-label uncontrolled clinical study. Eur J Ophthalmol 17: 230-237. (Pubitemid 46918110)
19. Krebs I, Lie S, Stolba U, Zeiler F, Felke S, &, Binder S, (2009): Efficacy of intravitreal bevacizumab (Avastin) therapy for early and advanced neovascular age-related macular degeneration. Acta Ophthalmol 87: 611-617.
20. Lazic R, &, Gabric N, (2007): Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 245: 68-73. (Pubitemid 46766732)
21. Macular Photocoagulation Study Group (1991): Subfoveal neovascular lesions in age-related macular degeneration. Guidelines for evaluation and treatment in the Macular Photocoagulation Study. Arch Ophthalmol 109: 1242-1257.
22. Madhusudhana KC, Hannan SR, Williams CP, Goverdhan SV, Rennie C, Lotery AJ, Luff AJ, &, Newsom RS, (2007): Intravitreal bevacizumab (Avastin) for the treatment of choroidal neovascularization in age-related macular degeneration: results from 118 cases. Br J Ophthalmol 91: 1716-1717. (Pubitemid 350207411)
23. Melamud A, Stinnett S, &, Fekrat S, (2008): Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections. Am J Ophthalmol 146: 91-95.
24. Moshfeghi AA, Rosenfeld PJ, Puliafito CA, Michels S, Marcus EN, Lenchus JD, &, Venkatraman AS, (2006): Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology 113: 2002. e1-12.
25. Ng EW, &, Adamis AP, (2005): Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can J Ophthalmol 40: 352-368. (Pubitemid 40942262)
26. Rich RM, Rosenfeld PJ, Puliafito CA, et al., (2006): Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 26: 495-511. (Pubitemid 44620390)
27. Spaide RF, Laud K, Fine HF, et al., (2006): Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 26: 383-390. (Pubitemid 44197628)
28. Weigert G, Michels S, Sacu S, Varga A, Prager F, Geitzenauer W, &, Schmidt-Erfurth U, (2008): Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study. Br J Ophthalmol 92: 356-360. (Pubitemid 351363530)
29. Wong TY, Chakravarthy U, Klein R, et al., (2008): The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. Ophthalmology 115: 116-126.
30. Wu L, Martinez-Castellanos MA, Quiroz-Mercado H, et al., (2008): Twelve-month safety of intravitreal injections of bevacizumab (Avastin®): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 246: 81-87. (Pubitemid 350167096)
31. Yannuzzi LA, Negrao S, Iida T, et al., (2001): Retinal angiomatous proliferation in age-related macular degeneration. Retina 21: 416-434. (Pubitemid 32971350)
32. Yoganathan P, Deramo VA, Lai JC, Tibrewala RK, &, Fastenberg DM, (2006): Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration. Retina 26: 994-998. (Pubitemid 44973217)